Akari Therapeutics

AKTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.32

+$0.07 (+0.85%)

Nov 2, 2026, 10:57 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.85%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

32.2

+3.0 pts

Fundamentals Weak

Market Sentiment Neutral

Moat None

Sector Rank #731/1028 (Top 71%)

Full Analysis

Key Statistics

Market Data

Market Cap $19.1M

1D Range

7.94 8.63

52W Range

3.06 32.80

Valuation (TTM)

PE -0.01

PB 1.02

EV/EBITDA -0.37

Valuation (NTM)

Forward PE N/A

Forward PEG -0.00

Price Target $24.75

Cash Flow

FCF Yield -56.8%

SBC Adj. FCF Yield -68.4%

SBC Impact -20.5%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 76.8% | 50.0%

FCF 3Y | 5Y 21.3% | 14.9%

Returns

ROA -80.2%

ROE -147.4%

ROIC -115.2%

Financial Health

Net Cash

$7M

Current Ratio 0.60

Interest Coverage -31.49

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immun...

Sector Healthcare

Industry Biotechnology

Employees 6

IPO Date Jan 6, 2014

Website www.akaritx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$24.75

Upside

+197.48%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞